Key clinical point: Hepatic arterial infusion (HAI)-fluorouracil-oxaliplatin-irinotecan (FOLFIRINOX) has a similar efficacy but worse safety profile compared with HAI-oxaliplatin in patients with liver metastases from colorectal cancer (LMCRC) resistant to previous lines of therapy.
Major finding: HAI-FOLFIRINOX vs HAI-oxaliplatin did not significantly improve the median overall survival (17.0 vs 26.2 months; P = .1), median progression-free survival (5.9 vs 6.4 months; P = .6), or objective response rate (43.2% vs 45.9%) but led to significantly higher secondary hepatic resection (35.6% vs 16.7%; P = .007) and grade ≥2 toxicity rates.
Study details: The data come from a multicenter, retrospective study that included 273 patients with LMCRC who had undergone ≥1 chemotherapy protocols and received HAI-oxaliplatin (n = 221) or HAI-FOLFIRINOX (n = 52).
Disclosures: No source of funding was disclosed. The authors declared no conflicts of interest.
Source: Randrian V et al. Hepatic arterial infusion chemotherapy with Folfirinox or oxaliplatin alone in metastatic colorectal cancer. Front Med (Lausanne). 2022;9:830595 (Jun 16). Doi: 10.3389/fmed.2022.830595